Cellectar Biosciences

About Cellectar Biosciences

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for cancer treatment. Their core objective is to leverage their proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to create next-generation cancer cell-targeting therapies with improved efficacy and safety by reducing off-target effects.

Products & Services

Iopofosine I 131:A small-molecule PDC designed for targeted delivery of iodine-131 (radioisotope) to treat cancer.

Preclinical PDC Chemotherapeutic Programs:Proprietary programs in development utilizing different payloads for cancer treatment.

Partnered PDC Assets:Multiple partnered assets using the PDC delivery platform for cancer therapies.

Specialties

Cancer Treatment Phospholipid Drug Conjugate™ (PDC) Delivery Platform Targeted Radiotherapy Chemotherapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 5800000 MR: - FA: approximately $5.8 million FAN: 5800000	D: 2025-10-07 FD: 2025-10-07	1 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6900000 MR: - FA: $6.9 million FAN: 6900000	D: 2025-07-02 FD: 2025-07-02	2 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6000000 MR: - FA: approximately $6 million FAN: 6000000	D: 2025-07-01 FD: 2025-07-01	1 investors
4	RT: Equity Financing T: - FT: Equity Financing	A: 2500000 MR: - FA: 2.5 million FAN: 2500000	D: 2025-06-05 FD: 2025-06-05	-
5	RT: Warrant Exercise and Purchase T: - FT: Warrant Exercise and Purchase	A: 19400000 MR: - FA: approximately $19.4 million FAN: 19400000	D: 2024-07-22 FD: 2024-07-22	1 investors
6	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 44100000 MR: - FA: 44.1 million FAN: 44100000	D: 2024-01-25 FD: 2024-01-25	1 investors
7	RT: Private Placement T: - FT: Private Placement	A: 103000000 MR: - FA: up to approximately $103 million FAN: 103000000	D: 2023-09-11 FD: 2023-09-11	6 investors

Warrant Exercise Latest

2025-10-07

$5.8M

1 investor (Pro only)

Underwritten Public Offering 2025-07-02

$6.9M

Underwritten Public Offering 2025-07-01

$6.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Douglas J. Swirsky

Chairman of the Board

J

James Caruso

President, CEO and Director

A

Asher Alban Chanan-Khan

Director

F

Frederick W. Driscoll

Director

S

Stefan D. Loren

Director

J

John Neis

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News